vs
Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and REGIS CORP (RGS). Click either name above to swap in a different company.
REGIS CORP is the larger business by last-quarter revenue ($57.1M vs $38.3M, roughly 1.5× ImmunityBio, Inc.). REGIS CORP runs the higher net margin — 0.8% vs -161.8%, a 162.6% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 22.3%). REGIS CORP produced more free cash flow last quarter ($891.0K vs $-71.3M).
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
REGIS CORPRGSEarnings & Financial Report
Regis Corporation is an American operator of hair salons. As of August 2021, it has 5,563 franchised and 276 company-owned salons. Its headquarters are in Minneapolis, Minnesota.
IBRX vs RGS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $38.3M | $57.1M |
| Net Profit | $-61.9M | $456.0K |
| Gross Margin | 99.0% | — |
| Operating Margin | -169.0% | 10.8% |
| Net Margin | -161.8% | 0.8% |
| Revenue YoY | 407.0% | 22.3% |
| Net Profit YoY | -4.7% | -94.0% |
| EPS (diluted) | $-0.06 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.3M | $57.1M | ||
| Q3 25 | $32.1M | $59.0M | ||
| Q2 25 | $26.4M | $60.4M | ||
| Q1 25 | $16.5M | $57.0M | ||
| Q4 24 | $7.6M | $46.7M | ||
| Q3 24 | $6.1M | $46.1M | ||
| Q2 24 | — | $49.4M | ||
| Q1 24 | — | $49.2M |
| Q4 25 | $-61.9M | $456.0K | ||
| Q3 25 | $-67.3M | $1.4M | ||
| Q2 25 | $-92.6M | $116.5M | ||
| Q1 25 | $-129.6M | $250.0K | ||
| Q4 24 | $-59.2M | $7.6M | ||
| Q3 24 | $-85.7M | $-853.0K | ||
| Q2 24 | — | $91.2M | ||
| Q1 24 | — | $-2.3M |
| Q4 25 | 99.0% | — | ||
| Q3 25 | 99.4% | — | ||
| Q2 25 | 99.5% | — | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -169.0% | 10.8% | ||
| Q3 25 | -173.5% | 10.0% | ||
| Q2 25 | -269.8% | 12.1% | ||
| Q1 25 | -390.1% | 8.8% | ||
| Q4 24 | -919.0% | 11.8% | ||
| Q3 24 | -1314.3% | 4.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 8.3% |
| Q4 25 | -161.8% | 0.8% | ||
| Q3 25 | -209.8% | 2.3% | ||
| Q2 25 | -350.3% | 192.9% | ||
| Q1 25 | -784.9% | 0.4% | ||
| Q4 24 | -783.4% | 16.4% | ||
| Q3 24 | -1404.0% | -1.9% | ||
| Q2 24 | — | 184.7% | ||
| Q1 24 | — | -4.7% |
| Q4 25 | $-0.06 | $0.16 | ||
| Q3 25 | $-0.07 | $0.49 | ||
| Q2 25 | $-0.10 | $43.67 | ||
| Q1 25 | $-0.15 | $0.08 | ||
| Q4 24 | $-0.08 | $2.71 | ||
| Q3 24 | $-0.14 | $-0.36 | ||
| Q2 24 | — | $38.40 | ||
| Q1 24 | — | $-1.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $242.8M | $18.4M |
| Total DebtLower is stronger | — | $113.3M |
| Stockholders' EquityBook value | $-500.5M | $188.7M |
| Total Assets | $501.9M | $588.3M |
| Debt / EquityLower = less leverage | — | 0.60× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $242.8M | $18.4M | ||
| Q3 25 | $257.8M | $16.6M | ||
| Q2 25 | $153.7M | $17.0M | ||
| Q1 25 | $61.6M | $13.3M | ||
| Q4 24 | $149.8M | $10.2M | ||
| Q3 24 | $130.4M | $6.3M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | — | $5.9M |
| Q4 25 | — | $113.3M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $110.8M | ||
| Q1 25 | — | $112.0M | ||
| Q4 24 | — | $111.5M | ||
| Q3 24 | — | $95.2M | ||
| Q2 24 | — | $99.5M | ||
| Q1 24 | — | $179.7M |
| Q4 25 | $-500.5M | $188.7M | ||
| Q3 25 | $-524.3M | $187.6M | ||
| Q2 25 | $-570.7M | $185.6M | ||
| Q1 25 | $-591.4M | $68.6M | ||
| Q4 24 | $-489.1M | $66.7M | ||
| Q3 24 | $-745.1M | $56.4M | ||
| Q2 24 | — | $56.8M | ||
| Q1 24 | — | $-35.8M |
| Q4 25 | $501.9M | $588.3M | ||
| Q3 25 | $519.0M | $592.1M | ||
| Q2 25 | $402.1M | $599.0M | ||
| Q1 25 | $303.8M | $511.2M | ||
| Q4 24 | $382.9M | $530.1M | ||
| Q3 24 | $364.6M | $508.9M | ||
| Q2 24 | — | $530.5M | ||
| Q1 24 | — | $543.7M |
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-70.4M | $1.7M |
| Free Cash FlowOCF − Capex | $-71.3M | $891.0K |
| FCF MarginFCF / Revenue | -186.2% | 1.6% |
| Capex IntensityCapex / Revenue | 2.4% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 3.65× |
| TTM Free Cash FlowTrailing 4 quarters | $-308.8M | $14.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-70.4M | $1.7M | ||
| Q3 25 | $-68.9M | $2.3M | ||
| Q2 25 | $-79.7M | $6.8M | ||
| Q1 25 | $-85.9M | $6.2M | ||
| Q4 24 | $-85.1M | $2.1M | ||
| Q3 24 | $-98.8M | $-1.3M | ||
| Q2 24 | — | $5.1M | ||
| Q1 24 | — | $-277.0K |
| Q4 25 | $-71.3M | $891.0K | ||
| Q3 25 | $-69.6M | $1.9M | ||
| Q2 25 | $-80.8M | $6.2M | ||
| Q1 25 | $-87.0M | $5.9M | ||
| Q4 24 | $-87.3M | $1.7M | ||
| Q3 24 | $-101.6M | $-1.4M | ||
| Q2 24 | — | $5.1M | ||
| Q1 24 | — | $-326.0K |
| Q4 25 | -186.2% | 1.6% | ||
| Q3 25 | -217.2% | 3.2% | ||
| Q2 25 | -305.9% | 10.3% | ||
| Q1 25 | -526.9% | 10.3% | ||
| Q4 24 | -1155.4% | 3.6% | ||
| Q3 24 | -1663.2% | -3.0% | ||
| Q2 24 | — | 10.3% | ||
| Q1 24 | — | -0.7% |
| Q4 25 | 2.4% | 1.4% | ||
| Q3 25 | 2.3% | 0.7% | ||
| Q2 25 | 4.1% | 0.9% | ||
| Q1 25 | 6.8% | 0.6% | ||
| Q4 24 | 28.0% | 0.9% | ||
| Q3 24 | 45.7% | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | 3.65× | ||
| Q3 25 | — | 1.68× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 24.80× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IBRX
Segment breakdown not available.
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
